Ace the Case: A 24-Year-Old Man With a History of Ulcerative Colitis and Abnormal Liver Tests healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
E-Mail
ATS 2021, New York, NY - By removing race correction from the interpretation of pulmonary function test (PFT) results, Black individuals were shown to have a significantly higher prevalence and severity of lung disease, according to research presented at the ATS 2021 International Conference.
Alexander Moffett, MD, clinical fellow, Division of Pulmonary, Allergy and Critical Care, University of Pennsylvania Perelman School of Medicine, and colleagues, sought to determine the real-world consequences of race correction for the interpretation of PFT results. Race correction, a standard practice in PFT interpretation that has no biological basis, results in a decrease in the predicted lower limit of normal for FEV1 (the maximum amount of air a person can forcibly exhale in one second) and FVC (forced vital capacity maximum amount exhaled forcefully after breathing in deeply) for Black patients.
BRCA variants, results of a small phase II trial showed.
A patient cohort with germline and somatic mutations, including
PALB2, had a 6-month progression-free survival (PFS) of 59.5%, decreasing only slightly to 54.5% at 12 months with maintenance rucaparib (Rubraca). The overall response rate of 41.7% included patients with germline (g) and somatic (s)
BRCA1/2 mutations and those with
PALB2 variants. Two-thirds of patients obtained disease control with the PARP inhibitor, according to Kim A. Reiss, MD, of University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues.
The results supported and extended those from the practicing-changing POLO trial of olaparib (Lynparza) maintenance for g